Patents Assigned to Supernus Pharmaceuticals, Inc.
  • Process of making derivatives of substituted morpholines
    Patent number: 11964951
    Abstract: Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 7, 2023
    Date of Patent: April 23, 2024
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Yanjun Sun, Bhaskara Rao Nallaganchu, Gary L. Olson
  • Derivatives of substituted morpholines and uses thereof
    Patent number: 11919889
    Abstract: A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: March 5, 2024
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventor: Janak Khimchand Padia
  • Method of treatment of CNS disorders
    Patent number: 11911368
    Abstract: The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and ?-opioid agonistic activity.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: February 27, 2024
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventor: Christopher D. Breder
  • Modified release preparations containing oxcarbazepine and derivatives thereof
    Patent number: 11896599
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 13, 2024
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • FORMULATIONS OF VILOXAZINE
    Publication number: 20230381191
    Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
    Type: Application
    Filed: August 10, 2023
    Publication date: November 30, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Michael L. Vieira, Austin B. Huang, Padmanabh P. Bhatt
  • METHOD OF TREATMENT OF CNS DISORDERS
    Publication number: 20230355589
    Abstract: The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and ?-opioid agonistic activity
    Type: Application
    Filed: July 17, 2023
    Publication date: November 9, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventor: Christopher D. Breder
  • PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES
    Publication number: 20230357173
    Abstract: Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 7, 2023
    Publication date: November 9, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Yanjun Sun, Bhaskara Rao Nallaganchu, Gary L. Olson
  • PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES
    Publication number: 20230295100
    Abstract: Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 17, 2023
    Publication date: September 21, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Yanjun Sun, Bhaskara Rao Nallaganchu, Gary L. Olson
  • OSMOTIC DRUG DELIVERY SYSTEM
    Publication number: 20230255892
    Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
    Type: Application
    Filed: November 21, 2022
    Publication date: August 17, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Padmanabh P Bhatt
  • FORMULATIONS OF MAZINDOL
    Publication number: 20230210823
    Abstract: Formulations of mazindol having superior stability and methods of administering same are provided. The formulations may be immediate, enhanced, or otherwise delayed release formulations of mazindol.
    Type: Application
    Filed: August 9, 2022
    Publication date: July 6, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Padmanabh P. Bhatt
  • Method of treatment of aggression
    Patent number: 11638708
    Abstract: The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: May 2, 2023
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventor: Christopher D. Breder
  • Derivatives of substituted morpholines and uses thereof
    Patent number: 11634415
    Abstract: A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: April 25, 2023
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventor: Janak Khimchand Padia
  • METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)
    Publication number: 20230102784
    Abstract: The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
    Type: Application
    Filed: August 26, 2022
    Publication date: March 30, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventor: Christopher D. BREDER
  • USE OF HIGHER DOSES OF MODIFIED RELEASE HUPERZINE FORMULATIONS
    Publication number: 20230090653
    Abstract: The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.
    Type: Application
    Filed: June 3, 2022
    Publication date: March 23, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Stephen D. COLLINS, Peter J. GOLDSTEIN, Joshua T. JOHNSTONE
  • MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF
    Publication number: 20230081113
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Application
    Filed: November 15, 2022
    Publication date: March 16, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. BHATT, Argaw KIDANE, Kevin EDWARDS
  • Method of treatment of attention deficit/hyperactivity disorder (ADHD)
    Patent number: 11458143
    Abstract: The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: October 4, 2022
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventor: Christopher D. Breder
  • DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF
    Publication number: 20220306618
    Abstract: A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester.
    Type: Application
    Filed: March 18, 2022
    Publication date: September 29, 2022
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventor: Janak Khimchand Padia
  • DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF
    Publication number: 20220298150
    Abstract: A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester.
    Type: Application
    Filed: May 25, 2022
    Publication date: September 22, 2022
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventor: Janak Khimchand Padia
  • METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)
    Publication number: 20220233548
    Abstract: The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
    Type: Application
    Filed: April 12, 2022
    Publication date: July 28, 2022
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventor: Christopher D. BREDER
  • Use of higher doses of modified release huperzine formulations
    Patent number: 11351120
    Abstract: The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: June 7, 2022
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Stephen D. Collins, Peter J. Goldstein, Joshua T. Johnstone